Boehringer Ingelheim, the largest private pharmaceutical company, focuses on: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Patients’ journey suffering from rare diseases like ILDs/IPF can take several months from the first suspicion to diagnosis. To improve the journey of patients suffering from IPF/ILDs, two challenges need to be addressed: access to the right expertise as fast as possible and reduce the time for diagnosis. With Medicai, we have reduced the time for diagnosis for IPF patients to only 3–4 months from at least 12 months, by integrating with 4 centers of excellence in Romania and making it very easy for experts to access patient data in the hospital, as well as remotely through Microsoft Azure.

**At-a-glance:**

- **Customer:** Boehringer Ingelheim
- **Website:** [www.boehringer-ingelheim.com](http://www.boehringer-ingelheim.com)
- **Customer Size:** 50000 employees
- **Country:** Germany, Ingelheim am Rhein
- **Industry:** Healthcare
- **Products and Services:** Microsoft Azure
Customer challenges
Patients suffering from chronic and rare diseases like IPF, take too long to receive the right diagnosis and treatment (sometimes years). Our partner’s collaborating centers had issues in triaging the medical cases and collecting the information for efficient doctor board meetings. The lack of a technology system meant some patients cases were lost among the pile of new incoming cases and getting the proper diagnostic took too much time.
On the patient side there was no clear way to reach the right experts, especially for rare diseases.

Partner Solution
Medicai was integrated in the 4 centers of excellence and the journey from suspicion to diagnosis was improved. The patient and the local specialist can now organize the medical data efficiently and, thanks to our Microsoft Azure cloud infrastructure, can access it securely from anywhere and easily share it. The time to diagnostic was reduced to just 3-4 months from 12+ months previously. Patients with an IPF suspicion from anywhere in the country have easy access to the right IPF experts on Medicai. Doctors organize video multidisciplinary team (MDT) meetings in the app and they sign-off on an IPF diagnostic using the document signing functionality.

Customer Benefits
“With Medicai, we have access to the patient medical data like CT scans and other medical documents. For more than a year now, we have organized our multidisciplinary discussions of diffuse interstitial lung diseases online, using the Medicai platform. The purpose of these discussions is to establish a definite diagnosis and to bring consensus on the therapeutic recommendations.” – Md. Phd. Claudia Toma, Senior Lecturer and Head of Pulmonology Department, Expert Pulmonologist with IPF/ILDs

65% decrease in the time it takes for patients to be diagnosed from their first HR-CT investigation: from 12 months to 3-4 months.

4 centers of excellence in Romania in IPF/ILDs were integrated with Medicai.

Doubled the number of patients that benefited from treatment for IPF in 2020, compared to 2019.

Contact Us:
info@medicai.org
+1 (650) 899 0207

Learn More
https://medicai.io

Microsoft Partner